JP2007523943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523943A5 JP2007523943A5 JP2007500182A JP2007500182A JP2007523943A5 JP 2007523943 A5 JP2007523943 A5 JP 2007523943A5 JP 2007500182 A JP2007500182 A JP 2007500182A JP 2007500182 A JP2007500182 A JP 2007500182A JP 2007523943 A5 JP2007523943 A5 JP 2007523943A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oligonucleotide
- tumor
- tgf
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000272 Oligonucleotide Polymers 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 5
- 102000003814 Interleukin-10 Human genes 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 229940076144 Interleukin-10 Drugs 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010027476 Metastasis Diseases 0.000 claims description 3
- 201000008808 fibrosarcoma Diseases 0.000 claims description 3
- 238000005755 formation reaction Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010044325 Trachoma Diseases 0.000 claims 2
- 241000390203 Trachoma Species 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000003511 endothelial Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000004404 neurofibroma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 208000004064 Acoustic Neuroma Diseases 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 208000002445 Cystadenocarcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 206010024190 Leiomyosarcomas Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010024627 Liposarcoma Diseases 0.000 claims 1
- 206010025224 Lymphangiosarcomas Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027191 Meningioma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000004019 Papillary Adenocarcinoma Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010073145 Soft tissue cancer Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 208000008383 Wilms Tumor Diseases 0.000 claims 1
- 201000003076 angiosarcoma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000009051 embryonal carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 230000001926 lymphatic Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000004458 myoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000582 retinoblastoma Diseases 0.000 claims 1
- 201000010208 seminoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 108010037805 Transforming growth factor beta-1 Proteins 0.000 description 6
- 102100014320 TGFB1 Human genes 0.000 description 5
- 229940099456 Transforming Growth Factor Beta 1 Drugs 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- 230000003305 autocrine Effects 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 108020003566 Antisense Oligodeoxyribonucleotides Proteins 0.000 description 2
- 239000003293 antisense oligodeoxyribonucleotide Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400000716 Transforming growth factor beta-1 Human genes 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Description
インタ−ロイキン10(IL−10)によりそれが免疫応答の制御に中心的な役割を果たすことが知られている。一部のインタ−ロイキン10のアンチセンスオリゴヌクレオチドが細胞媒介免疫応答を増強することが示されたため、腫瘍細胞の回避機構を補填し腫瘍成長を阻害して転移形成を減少させる方法において、免疫応答を調節するためにヒトにおけるIL−10の強力な阻害剤を見出すことが重要であった。
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
国際公開第99/63975号パンフレット
国際公開第94/25588号パンフレット
スパーマン M(Sperman M)ら、「マウス線維肉腫細胞の増殖及び悪性特性におけるアンチセンスオリゴデオキシリボヌクレオチドによるTGF−ベータ1遺伝子発現及び選択阻害(Antisense oligodeoxyribonucleotide inhibition of TGF−beta1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells)」,遺伝子(GENE),Elsevier Biomedical Press.,オランダ アムステルダム,第149巻,1994年,p.25−29
ハング フェイ(Huang Fei)ら,「TGF−ベータ−1アンチセンス発現プラスミドのトランスフェクションによって示したように、形質転換成長因子β1(TGF−β−1)はインビボにおいて大腸癌U9細胞の自己分泌における正の調整因子である(Transforming growth factor beta−1(TGF−beta−1)is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF−beta−1 antisense expression plasmid)」,細胞増殖と分化(Cell Growth and Differentiation),第6巻,第12号,1995年,p.1635−1642
ジャチムザック P(Jachimczak P)ら,「ホスホロチオエートアンチセンスオリゴヌクレオチドを用いて検出した場合の形質転換成長因子βを介在した神経膠腫の自己分泌増殖調節(Transforming Growth Factor−beta−mediated Autocrine Growth Regulation of Gliomas as Detected with Phosphorothioate Antisense Oligonucleotides)」,国際癌雑誌(International Journal of Cancer),米国ニューヨーク州ニューヨーク,第65巻,第3号,1996年,p.332−337
ピコン アントニオ(Picon Antonio)ら,「転移ヒト大腸癌サブセットによる形質転換成長因子ベータ1レベルの上昇(A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1)」,癌疫学生体指標と予防(Cancer Epidemiology Biomarkers and prevention),第7巻,第6号,1998年,p.497−504
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
Claims (6)
- 少なくとも1つのオリゴヌクレオチドであって、
配列ID番号1〜107において示した配列において同定されるもの、或いは癌治療における転移形成を阻害するための実施例19〜24において特定されるものである、
少なくとも1つのオリゴヌクレオチド。 - 請求項1記載のオリゴヌクレオチドにおいて、前記オリゴヌクレオチドは、前記転移形成に関与するタンパク質の合成を阻害するアンチセンスオリゴヌクレオチドである。
- 請求項1又は2記載のオリゴヌクレオチドにおいて、前記オリゴヌクレオチドは、TGF−ベータ1、TGF−ベータ2、TGF−ベータ3、及び/又はインターロイキン10の生成を阻害するアンチセンスオリゴヌクレオチドである。
- 請求項1〜3いずれかに記載のオリゴヌクレオチドにおいて、前記オリゴヌクレオチドは、配列ID番号1、5、6、8、9、14、15、16、28、29、30、34、35、36、40、又は42において示した配列において特定されるものである。
- 請求項1〜4のいずれかに記載のオリゴヌクレオチドにおいて、前記癌は、胆管癌、膀胱癌、脳腫瘍、乳癌、気管支癌、腎臓癌、子宮頸癌、絨毛癌、嚢胞腺癌、子宮頸癌、結腸癌、結腸直腸癌、胚性癌腫、子宮内膜癌、上皮性癌、食道癌、嚢胞癌、胃癌、頭頸部癌、肝細胞癌、白血病、肝臓癌、肺癌、リンパ腫、髄様癌、非小細胞気管支/胚癌、卵巣癌、膵臓癌、乳頭癌、乳頭腺癌、前立腺癌、小腸癌、直腸癌、腎臓細胞癌、脂腺癌、皮膚癌、非小細胞気管支/肺癌、軟組織癌、扁平上皮細胞癌、睾丸癌、子宮癌、聴神経腫瘍、神経線維腫、トラコーマ、及び化膿性肉芽腫、前癌状態の腫瘍、芽細胞腫、ユーイング腫瘍、頭蓋咽頭腫、上衣細胞腫、髄芽細胞腫、血管細胞腫、髄芽細胞腫、メラノーマ、中皮腫、神経芽腫、神経線維腫、松果体腫、網膜芽細胞腫、肉腫(血管肉腫、軟骨肉腫、内皮性肉腫、線維肉腫、神経膠腫、平滑筋肉腫、脂肪肉腫、リンパ内皮性肉腫、リンパ管肉腫、メラノーマ、髄膜腫、筋肉腫、骨原性肉腫、骨肉腫を含む)、セミノーマ、トラコーマ、ウィルムス腫瘍、及び/又は多発性骨髄腫の群から選択されるものである。
- 請求項1〜5のいずれかに記載のアンチセンスオリゴヌクレオチドを含む薬学的組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04004478.6 | 2004-02-27 | ||
EP04004478A EP1568383A3 (en) | 2004-02-27 | 2004-02-27 | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
US55813504P | 2004-04-01 | 2004-04-01 | |
US60/558,135 | 2004-04-01 | ||
PCT/EP2005/002101 WO2005084712A2 (en) | 2004-02-27 | 2005-02-28 | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007523943A JP2007523943A (ja) | 2007-08-23 |
JP2007523943A5 true JP2007523943A5 (ja) | 2008-04-24 |
JP5650367B2 JP5650367B2 (ja) | 2015-01-07 |
Family
ID=34921301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007500182A Expired - Fee Related JP5650367B2 (ja) | 2004-02-27 | 2005-02-28 | 医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070155685A1 (ja) |
EP (1) | EP1722823A2 (ja) |
JP (1) | JP5650367B2 (ja) |
AU (2) | AU2005218759B2 (ja) |
CA (1) | CA2558667A1 (ja) |
IL (1) | IL177480A0 (ja) |
MX (1) | MXPA06009794A (ja) |
WO (1) | WO2005084712A2 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101543B2 (en) | 2000-03-31 | 2006-09-05 | Novarx | Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells |
US6784291B2 (en) * | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
DK1456380T3 (da) * | 2001-11-02 | 2012-07-30 | Giuliani Int Ltd | SMAD7-inhibitorer til behandling af CNS-sygdomme |
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
EP2062586B1 (en) * | 2005-05-05 | 2017-03-15 | Autotelic LLC | Use of low doses of oligonucleotides antisense to tgf-beta1 genes in the treatment of tumors |
WO2007048857A1 (es) * | 2005-10-24 | 2007-05-03 | Proyecto De Biomedicina Cima, S.L. | USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE |
GB0604966D0 (en) * | 2006-03-11 | 2006-04-19 | Renovo Ltd | Medicaments and proteins |
US20080081031A1 (en) * | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
CA2673793C (en) * | 2007-02-16 | 2016-01-26 | The Johns Hopkins University | Micrornas for diagnosis and treatment of cancer |
CA2710013A1 (en) | 2007-12-28 | 2009-07-09 | Avi Biopharma, Inc. | Immunomodulatory agents and methods of use |
US8822425B2 (en) * | 2008-11-14 | 2014-09-02 | Antisense Pharma Gmbh | Dosage of oligonucleotides suitable for the treatment of tumors |
ES2347627B1 (es) * | 2009-03-06 | 2011-10-10 | Isdin, S.A. | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. |
AU2010277554B2 (en) * | 2009-07-30 | 2015-02-19 | Antisense Pharma Gmbh | Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system |
JP2013531981A (ja) | 2010-06-11 | 2013-08-15 | アンチセンス・ファーマ・ゲーエムベーハー | 選択的オリゴヌクレオチド修飾の方法 |
EP2453017A1 (en) * | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
WO2012100931A1 (en) * | 2011-01-24 | 2012-08-02 | Eth Zurich | New medical uses of tgf beta 1- specific irna |
CA2865468C (en) | 2011-03-11 | 2021-05-04 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
PL2978844T3 (pl) * | 2013-03-27 | 2021-01-25 | Isarna Therapeutics Gmbh | Modyfikowane oligonukleotydy tgf-beta2 |
HUE049246T2 (hu) | 2013-03-27 | 2020-09-28 | Isarna Therapeutics Gmbh | Módosított TGF-béta-oligonukleotid szemészeti betegségek megelõzésére és/vagy kezelésére szolgáló eljárásban történõ felhasználásra |
CA2908096C (en) | 2013-03-27 | 2022-05-03 | Isarna Therapeutics Gmbh | Modified tgf-beta oligonucleotides |
US20150197534A1 (en) * | 2013-09-05 | 2015-07-16 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
US20170173180A1 (en) * | 2014-03-27 | 2017-06-22 | The Regents Of The University Of Michigan | Cancer immunotherapy compositions and methods |
CN107428825A (zh) * | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
WO2016182513A1 (en) * | 2015-05-13 | 2016-11-17 | Singapore Health Services Pte Ltd | Profiling of hepatocellular carcinoma and applications thereof |
US10787664B2 (en) * | 2015-05-26 | 2020-09-29 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
EP3341012A4 (en) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
CN114144423A (zh) * | 2018-12-27 | 2022-03-04 | 圣诺制药公司 | 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症 |
EP4416285A1 (en) * | 2021-10-13 | 2024-08-21 | University College Dublin, National University of Ireland | Nucleic acid agents for treatment of non-small-cell lung cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4452775A (en) * | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4999339A (en) * | 1988-03-28 | 1991-03-12 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5550316A (en) * | 1991-01-02 | 1996-08-27 | Fox Chase Cancer Center | Transgenic animal model system for human cutaneous melanoma |
US5714331A (en) * | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5369527A (en) * | 1992-12-03 | 1994-11-29 | Mccracken; Robert | Melanoma detection device |
WO1994025588A2 (en) * | 1993-04-30 | 1994-11-10 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
US6153388A (en) * | 1994-10-27 | 2000-11-28 | University Of South Florida | Method of determining melanoma micrometastasis using tyrosinase |
US5843974A (en) * | 1995-06-06 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
EP0856579A1 (en) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
AUPO864097A0 (en) * | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
ATE274923T1 (de) * | 1998-06-10 | 2004-09-15 | Biognostik Ges | Stimulierung des immunsystems |
EP1133988A1 (en) * | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
US7101543B2 (en) * | 2000-03-31 | 2006-09-05 | Novarx | Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells |
US20040006030A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
JP4871732B2 (ja) * | 2003-12-19 | 2012-02-08 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
-
2005
- 2005-02-28 JP JP2007500182A patent/JP5650367B2/ja not_active Expired - Fee Related
- 2005-02-28 AU AU2005218759A patent/AU2005218759B2/en not_active Ceased
- 2005-02-28 MX MXPA06009794A patent/MXPA06009794A/es active IP Right Grant
- 2005-02-28 WO PCT/EP2005/002101 patent/WO2005084712A2/en active Application Filing
- 2005-02-28 EP EP05715605A patent/EP1722823A2/en not_active Ceased
- 2005-02-28 US US10/591,048 patent/US20070155685A1/en not_active Abandoned
- 2005-02-28 CA CA002558667A patent/CA2558667A1/en not_active Abandoned
-
2006
- 2006-08-14 IL IL177480A patent/IL177480A0/en unknown
-
2009
- 2009-09-28 AU AU2009222442A patent/AU2009222442B2/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007523943A5 (ja) | ||
Li et al. | Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas | |
Fellenberg et al. | Prognostic significance of drug-regulated genes in high-grade osteosarcoma | |
Nottingham et al. | Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer | |
EP0856579A1 (en) | An antisense oligonucleotide preparation method | |
Roberts et al. | Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides | |
WO2005084712A3 (en) | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment | |
JP2010526797A5 (ja) | ||
EP2487254A3 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
Jahanafrooz et al. | Comparative evaluation of silibinin effects on cell cycling and apoptosis in human breast cancer MCF-7 and T47D cell lines | |
Chen et al. | THBS4 predicts poor outcomes and promotes proliferation and metastasis in gastric cancer | |
Lu et al. | Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival | |
Platais et al. | The role of HOX genes in head and neck squamous cell carcinoma | |
Wang et al. | Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms | |
Yamashita et al. | HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma | |
Chang et al. | The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells | |
Shakib et al. | Stem cells in head and neck squamous cell carcinoma | |
Hong et al. | Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA | |
Shen et al. | SNHG17, as an EMT‐related lncRNA, promotes the expression of c‐Myc by binding to c‐Jun in esophageal squamous cell carcinoma | |
Oswald et al. | In good times and bad: p73 in cancer | |
Lu et al. | Nuclear export as a novel therapeutic target: the CRM1 connection | |
Wachsmannova et al. | Changes in SNAI1 and VIM gene expression in Caco2 cells after co-cultivation with bacteria from colorectal cancer biopsies. | |
Harris | MDM2 splice variants and their therapeutic implications | |
Hsu et al. | Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu | |
Zhao et al. | Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis |